Roche signs antibody research and licensing agreement with Norway's Affitech |
|
|
|
Published
:
Sun, 06 May 2007 17:40 |
LONDON (Thomson Financial) - Affitech AS, the Norwegian human antibody therapeutics company, said it has signed a research and licensing agreement with Roche Holdings AG to produce fully human monoclonal antibodies.Affitech said it will use its technology to identify candidate antibodies which Roche would use for further development and commercialization.The financial terms of the collaboration include research fees, milestone payments and royalties on net sales upon commercialization of any product.tf.TFN-Europe_newsdesk@thomson.comwjCOPYRIGHTCopyright AFX News Limited 2007. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
|
|
|
|
|
|
|
| Stock
Quotes * |
|
NASDAQ
|
|
1617.01 |
+17.95 (
1.13 %)
|
| SYMBOL (
2009-01-08 ) |
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
| SYMBOL (
2009-01-08 )
|
| LAST |
CHANGE
|
|
| Portfolio
Manager |
|
|
|